|
Osteosarcoma
|
0.450 |
AlteredExpression
|
disease |
BEFREE |
Analysis of TCGA database showed that there was no substantial deviation in the expression of GRM4 between osteosarcoma and normal tissues.
|
31581881 |
2020 |
|
Osteosarcoma
|
0.450 |
Biomarker
|
disease |
BEFREE |
Agonists of GRM4 or a neutralizing antibody to IL23 suppressed osteosarcoma growth in mice.
|
31527131 |
2019 |
|
Osteosarcoma
|
0.450 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to investigate the association between polymorphism of the GRM4 gene and the susceptibility to osteosarcoma in a Chinese population.
|
26276359 |
2016 |
|
Osteosarcoma
|
0.450 |
AlteredExpression
|
disease |
BEFREE |
The results of Western blot and RT-PCR indicated a significantly increased expression level of mGluR4 gene and protein in osteosarcoma tissues compared with normal tissues.
|
24399291 |
2014 |
|
Osteosarcoma
|
0.450 |
GeneticVariation
|
disease |
BEFREE |
The GRM4 gene polymorphism was associated with the susceptibility and metastasis of OS in a Chinese Han population.
|
24984297 |
2014 |
|
Osteosarcoma
|
0.450 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association study identifies two susceptibility loci for osteosarcoma.
|
23727862 |
2013 |
|
Osteosarcoma
|
0.450 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study identifies two susceptibility loci for osteosarcoma.
|
23727862 |
2013 |
|
Osteosarcoma
|
0.450 |
Biomarker
|
disease |
CTD_human |
Genome-wide association study identifies two susceptibility loci for osteosarcoma.
|
23727862 |
2013 |
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
PSYGENET |
Changes in paired-pulse facilitation that became overt in the presence of the GABAA antagonist picrotoxin indicated a function of mGluR4 in maintaining the excitation/inhibition balance, which is of crucial importance for information processing in the brain and the deterioration of these processes in neuropsychological disorders such as autism, epilepsy and schizophrenia.
|
23714430 |
2013 |
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
BEFREE |
We conclude that at least one susceptibility locus for schizophrenia is located within or nearby GRM7, whereas GRM4 is unlikely to be a major susceptibility gene for schizophrenia in the Japanese population.
|
19351574 |
2009 |
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
PSYGENET |
We conclude that at least one susceptibility locus for schizophrenia is located within or nearby GRM7, whereas GRM4 is unlikely to be a major susceptibility gene for schizophrenia in the Japanese population.
|
19351574 |
2009 |
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
BEFREE |
Thus, this study did not provide evidence for the contribution of the mGluR4 gene to schizophrenia in the Japanese.
|
11525421 |
2001 |
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
PSYGENET |
Thus, this study did not provide evidence for the contribution of the mGluR4 gene to schizophrenia in the Japanese.
|
11525421 |
2001 |
|
Bipolar Disorder
|
0.300 |
Biomarker
|
disease |
PSYGENET |
Several candidate genes for schizophrenia may also be associated with bipolar disorder: G72, DISC1, NRG1, RGS4, NCAM1, DAO, GRM3, GRM4, GRIN2B, MLC1, SYNGR1, and SLC12A6.
|
17239033 |
2007 |
|
Nerve Degeneration
|
0.300 |
Therapeutic
|
phenotype |
CTD_human |
Functional role of mGluR1 and mGluR4 in pilocarpine-induced temporal lobe epilepsy.
|
17446080 |
2007 |
|
Bipolar Disorder
|
0.300 |
Biomarker
|
disease |
PSYGENET |
Six genes (DAO, GRM3, GRM4, GRIN2B, IL2RB, and TUBA8) met this criterion for bipolar I disorder; only DAO has been previously associated with bipolar disorder.
|
16380905 |
2005 |
|
Epilepsy, Temporal Lobe
|
0.300 |
Biomarker
|
disease |
CTD_human |
Here, we examine the transcription levels of mGluRs class I (mGluR1 and 5) and III (mGluR4 and 7) in experimental TLE and correlate differential mGluR subunit expression with mouse-strain-dependent susceptibility to TLE induced by pilocarpine.
|
15694259 |
2005 |
|
Uncinate Epilepsy
|
0.300 |
Biomarker
|
disease |
CTD_human |
Expression analysis of metabotropic glutamate receptors I and III in mouse strains with different susceptibility to experimental temporal lobe epilepsy.
|
15694259 |
2005 |
|
Epilepsy, Benign Psychomotor, Childhood
|
0.300 |
Biomarker
|
disease |
CTD_human |
Expression analysis of metabotropic glutamate receptors I and III in mouse strains with different susceptibility to experimental temporal lobe epilepsy.
|
15694259 |
2005 |
|
Epilepsy, Lateral Temporal
|
0.300 |
Biomarker
|
disease |
CTD_human |
Expression analysis of metabotropic glutamate receptors I and III in mouse strains with different susceptibility to experimental temporal lobe epilepsy.
|
15694259 |
2005 |
|
Parkinson Disease
|
0.060 |
Biomarker
|
disease |
BEFREE |
Modulation of presynaptic metabotropic glutamate receptor 4 (mGlu<sub>4</sub>) by an allosteric ligand has been proposed as a promising therapeutic target in Parkinson's disease and levodopa-induced dyskinesia.
|
30066121 |
2019 |
|
Parkinson Disease
|
0.060 |
Biomarker
|
disease |
BEFREE |
We also provide an update on clinical trials evaluating mGluR5 or mGluR4 ligands in PD.
|
29625424 |
2018 |
|
Parkinson Disease
|
0.060 |
Biomarker
|
disease |
BEFREE |
As class C GPCRs and regulators of synaptic activity, human metabotropic glutamate receptors (mGluRs) 4 and 5 are prime targets for allosteric modulation, with mGlu5 inhibition or mGlu4 stimulation potentially treating conditions like chronic pain and Parkinson's disease.
|
28694498 |
2017 |
|
Parkinson Disease
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
This work led to the identification of compound 40, a potent and selective mGluR4 positive allosteric modulator (PAM) with good water solubility and demonstrating consistent activity across validated preclinical rodent models of PD motor symptoms after intraperitoneal administration: haloperidol-induced catalepsy in mouse and the rat 6-hydroxydopamine (6-OHDA) lesion model.
|
28902994 |
2017 |
|
Parkinson Disease
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
We and others have used PAMs targeting mGlu4 to show that potentiation of receptor signaling induces antiparkinsonian activity in a variety of PD animal models, including haloperidol-induced catalepsy and 6-hydroxydopamine-induced lesion.
|
27441572 |
2016 |